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EFFECTS OF INTRAVESICAL INSTILLATION OF CYLOCIDE
   ON THE RECURRENCE RATE OF BLADDER’TUMORS
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   Intravesical instillation of Cylecide was carried out in 113 cases with urinary bladder tumors
fc r the purpose of prophylaxis of the recurrence ef bladder tumers after removal．
   Aqueous or saline・ solution containing Cylocide 200 mg was usually instilled into the bladder
Qnce every weck for 15 we． eks afte．．r op．eration ahd the tesults were foliowed up for from one to 4 years．
The actuarial recUrrehce rate of the 113 cases treated NNrith Cylocide was 25．1 O／． within one year， 38．70／，
within 2 years， 54．J“O／． within 3 and 4 years．
   No severL’h side’eff¢cts were observed during the instillation period， while bladder irritability was
co血plained in 30f I O8 cases（2．8％）and leukopeni4 was notiged in．50f l O2 cases（4．9％）． On the
results of our studies， it is concluded that the prophylagtic instillation therapy．with Cylocide is useful
for the prevention of recurrence of bladder tumors after removal．
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茎性，low grade， Iow stageのものがそうでないもの
に比べて再発率が低かった（Fig．2ん4）．
 3、術式別の再発率
 術式別症例数はTUR 84例， TUC 6例，部分切除
Table 1．機関別症例数
機  関  名 総症例数． 脱落例数※ 除外例数×※  対象例数
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Fig・1・CA膀胱内注入による膀胱腫瘍の再発率
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目able 3．要因別による再発率
再 発  率 再  発  率
要  因   症例数再発例数 0～降 1～2年2～3年3～4年要  因   症例数再発字数 O｝1年 1～2年2～3年3～4年
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   徳永・ほか：膀胱腫瘍・キロサイド注入療法
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    Fig・2・要因別による再発率（その1）
     Table 4－1．腫瘍の悪性度と術式
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      泌尿紀要：26巻 2号
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    徳永・ほか1膀胱腫瘍・キPサイド注入療法
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